Other Clinical Trial - Impact of Acquired FXIII Deficiency on Morbidity &

Clinical Trial Description

All patients admitted to a large tertiary hospital with FXIII levels below 70% during their hospital stay are assessed. Data regarding patient background, blood transfusion, morbidity and mortality is registered. ;

Study Design

Related Conditions & MeSH terms

Acquired Factor XIII Deficiency Disease
Deficiency Diseases
Factor XIII Deficiency

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04416594
Study type	Observational
Source	Hospital General Universitario Gregorio Marañon
Contact
Status	Completed
Phase
Start date	September 10, 2019
Completion date	May 18, 2020

Impact of Acquired FXIII Deficiency on Morbidity and Mortality

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms